4.1B is a member of the protein 4.1 superfamily of proteins that link transmembrane proteins to the actin cytoskeleton. The 4.1B gene localizes to chromosome 18p11.3, which undergoes loss of heterozygosity in mammary tumors. Here, we examine the expression of 4.1B in murine mammary epithelium and find that 4.1B is dramatically upregulated in mammary epithelial cells during pregnancy when there is extensive cell proliferation. In contrast, 4.1B is not expressed in virgin, lactating, or involuting mammary epithelium. To examine the consequence of 4.1B loss on mammary epithelial cell proliferation, we analysed mammary glands in 4.1B-null mice. 4.1B loss results in a significant increase in mammary epithelial cell proliferation during pregnancy, but has no effect on mammary epithelial cell proliferation, in virgin or involuting mice. Furthermore, we show that 4.1B inhibits the proliferation of mammary epithelial cell lines by inducing a G 1 cell cycle arrest, characterized by decreased cyclin A expression and reduced Rb phosphorylation, and accompanied by reduced erbB2 phosphorylation. This cell cycle arrest does not involve alterations in the activities of MAPK, JNK, or Akt. Collectively, our findings demonstrate that 4.1B regulates mammary epithelial cell proliferation during pregnancy and suggest that its loss may influence mammary carcinoma pathogenesis in multiparous women.
Introduction
Members of the protein 4.1 superfamily of proteins share structural homology with band 4.1R, a spectrinbinding protein that was originally isolated from human erythrocytes (Tyler et al., 1979) . This superfamily consists of five subgroups, including the 4.1 proteins (4.1R, 4.1N, 4.1G, 4.1O, and 4.1B) and the ERM proteins (ezrin, radixin, moesin, and merlin). All 4.1 family members are characterized by the presence of a conserved N-terminal membrane-association FERM (Fourpoint-one, Ezrin, Radixin, Moesin) domain (Chishti et al., 1998) . In addition, most 4.1 proteins can associate with the spectrin-actin cytoskeleton by virtue of an actin-binding domain (Parra et al., 2000; Gimm et al., 2002) . Both 4.1 and ERM proteins can act as structural proteins that link the plasma membrane to the actin cytoskeleton (Tsukita et al., 1994) .
A number of signaling functions have been attributed to 4.1 family members. In particular, growth suppressive functions have been identified for protein 4.1R and the merlin tumor suppressor protein, as overexpression of these proteins results in decreased cell proliferation (Lutchman and Rouleau, 1995; Robb et al., 2003) . Loss or inactivation of merlin, which shares high homology with ezrin, radixin, and moesin, is linked to neurofibromatosis type 2 (NF2), a disease characterized by the development of multiple nervous system tumors including schwannomas and meningiomas (Rouleau et al., 1993; Trofatter et al., 1993) .
Several lines of evidence suggest that protein 4.1B may also function as a tumor suppressor. Protein 4.1B is a brain-enriched ortholog of 4.1R that localizes to points of cell-cell contact at the plasma membrane (Peters et al., 1998; Parra et al., 2000) . Several studies have indicated that 4.1B expression is lost or reduced in numerous malignant and benign tumors, including 54% of nonsmall cell lung carcinomas (NSCLC) (Tran et al., 1999) . 4.1B is also reduced in 60% of sporadic meningiomas and 30% of ependymomas (Gutmann et al., 2000; Singh et al., 2002) . The 4.1B gene is located on band 18p11.3, a chromosomal region that has been shown to undergo frequent loss of heterozygosity (LOH) in these tumors (Tran et al., 1999; Gutmann et al., 2000; Singh et al., 2002) . Re-expression of 4.1B in NSCLC and meningioma cell lines causes in growth suppression, further supporting the possibility that 4.1B acts as a tumor suppressor (Tran et al., 1999; Gutmann et al., 2001 ).
4.1B has also been implicated as a tumor suppressor protein in mammary carcinomas, which also frequently develop LOH at band 18p11.3 (Tran et al., 1999; Kittiniyom et al., 2004) . Because loss of this region occurs with relatively high frequency in ductal carcinomas in situ (56%), it has been proposed to be an early event in tumor progression in the breast (Kittiniyom et al., 2001) . Furthermore, re-introduction of the minimal growth inhibitory domain of 4.1B, called DAL-1 (differentially expressed in adenocarcinoma of the lung), results in growth suppression in a number of mammary carcinoma cell lines (Charboneau et al., 2002) .
In order to elucidate the role of 4.1B in the normal mammary gland and how its loss might contribute to mammary tumorigenesis, we examined the expression pattern of 4.1B during postpubertal mammary gland development. Because the mammary gland is a dynamic tissue that undergoes extensive remodeling during its postpubertal development, it is an excellent model system in which to study a protein involved in growth regulation (Daniel and Smith, 1999) . The mature virgin mammary gland consists of a ductal tree that is comprised of generally quiescent epithelial cells that surround a central lumen, with some of these ductal branches ending in rudimentary alveolar buds. During pregnancy, the epithelial cells undergo a massive burst of proliferation in order to form more alveolar buds and differentiated alveoli that ultimately fill nearly the entire fat pad. During late pregnancy and lactation, these alveoli become fully differentiated and begin to secrete milk. Upon weaning, the mammary gland enters involution, a stage in which the secretory epithelial cells of the alveoli undergo apoptosis and the entire gland is remodeled so that it resembles the virgin gland (Richert et al., 2000) . Although the epithelium of the mammary gland undergoes a proliferative phase during pregnancy, the proliferation that occurs is tightly controlled and lasts for a defined period of time.
In this report, we show that 4.1B is not expressed in the epithelium of the virgin mouse mammary gland, but is dramatically upregulated during pregnancy and then downregulated again in the lactating and involuting glands. Exogenous expression of 4.1B in both mammary epithelial and carcinoma cell lines causes a significant inhibition of proliferation that results in a G 1 cell cycle arrest. Interestingly, although 4.1B-null mice do not form tumors of the mammary gland (Kissil et al., manuscript in preparation) , loss of 4.1B in these mice results in a significant increase in mammary epithelial cell proliferation during pregnancy. Collectively, our results demonstrate that 4.1B regulates cell cycle progression in proliferating mammary epithelium through a novel mechanism.
Results

Protein 4.1B expression is induced in mammary epithelia during pregnancy
Previous reports have suggested that protein 4.1B may function as a tumor suppressor protein whose expression is lost in breast cancers (Tran et al., 1998; Kittiniyom et al., 2001; Charboneau et al., 2002) . However, the role of 4.1B in normal mammary epithelium had not been previously tested. We therefore examined the expression of 4.1B in mammary glands from prepubertal virgin (day 16, data not shown), mature virgin (week 8), pregnant (13.5 days postcoitum (dpc)), lactating (9 days postpartum (dpp)), and involuting (1 day postweaning (dpw), data not shown, and 5 dpw) C57BL/6 mice to determine whether 4.1B expression changes in mammary epithelial cells that are quiescent, proliferating, fully differentiated, or undergoing apoptosis. Immunohistochemistry of paraffin-embedded sections revealed that 4.1B expression is virtually absent from epithelial cells in the mammary glands of virgin mice, but is dramatically induced in these cells during pregnancy (compare Figure  1a and b). By midlactation, however, 4.1B expression is significantly reduced or absent from these cells ( Figure 1c ) and is absent from the epithelial cells in involuting glands (Figure 1d ). Nearly all epithelial cells examined during pregnancy (12.5-14.5 dpc) were positive for 4.1B expression, indicating that the upregulation of this protein occurs throughout mammary gland epithelium. Specific labeling of 4.1B by the antibody used in these experiments was confirmed by staining mammary gland sections from pregnant (13.5 dpc) 4.1B-null mice (Figure 1b, inset) . Using this 4.1B antibody, weak immunoreactivity was detected in the lumen of some acini of both wild-type and 4.1B-null mice, indicating that this luminal staining was nonspecific (data not shown). Immunofluorescence of the wild-type pregnant (13.5 dpc) gland for 4.1B ( Figure 1e ) and E-cadherin ( Figure 1f ) and their overlay (Figure 1g) shows that 4.1B localizes predominantly to regions of cell-cell contact (Figure 1g , arrows) as well as at apical membranes, with some limited cytoplasmic expression.
We next quantified the changes in 4.1B expression during different phases of mammary development. The specificity of the 4.1B antibody was further verified by Western blot analysis of mammary gland lysates from wild-type and 4.1B-null mice at 13.5 dpc. Major bands with the predicted sizes of 4.1B isoforms were detected in the wild-type but not the 4.1B-null lysate, with only a limited number of nonspecific bands appearing in both lysates (Figure 1h ). Similar results were obtained in Western blots of wildtype lysates when the antibody was preincubated with 4.1B peptide (data not shown). The upregulation of 4.1B during pregnancy was then confirmed by Western blot analysis of stage-matched wild-type virgin, pregnant, lactating, and involuting whole mammary gland lysates. As shown in Figure 1i , 4.1B is dramatically induced during pregnancy coincident with the increased expression of the epithelial cell marker, E-cadherin. Weak 4.1B bands from nonpregnant mammary tissues can be detected with increased protein loading (not shown), likely resulting from 4.1B expression by vascular endothelial cells (Gutmann et al., 2000) . 4 .1B regulates mammary epithelial proliferation R Kuns et al Figure 1 Protein 4.1B expression in the normal mouse mammary gland. (a) Virgin (8 weeks), (b) pregnant (13.5 dpc), (c) lactating (9 dpp), and (d) involuting (5 dpw) mouse mammary glands were sectioned and stained for protein 4.1B. The inset (b) shows protein 4.1B staining of a mammary gland section from a 13.5 dpc pregnant 4.1B-null mouse to demonstrate the specificity of the protein 4.1B antibody. (e-g) Sections from the pregnant gland (13.5 dpc) were stained for protein 4.1B (e) and E-cadherin (f), and the images were overlaid to show localization of protein 4.1B at cell junctions (g, arrows) . (h, i) Immunoblotting of lysates from wild-type and 4.1B-null pregnant mammary glands (13.5 dpc) was performed to demonstrate (h) the specificity of the protein 4.1B antibody and (i) to quantify changes in the levels of protein 4.1B expression. Whole tissue lysates from 8 weeks virgin (V), 13.5 dpc pregnant (P), 9 dpp lactating (L), and 5 dpw involuting (I) glands were probed with an anti-4.1B antibody, an anti-E-cadherin antibody (to demonstrate epithelial cell contribution), and an anti-actin antibody (as a loading control). Note that, consistent with the immunostaining in panels a-d, a band specific for 4.1B is only detectable at significant levels during pregnancy 4.1B regulates mammary epithelial proliferation R Kuns et al
ERM proteins are downregulated during pregnancy
Although primarily known for its role as a structural protein, ezrin has been implicated in metastatic progression (Hunter, 2004) . Ezrin upregulation has been documented in a number of metastatic tumors (Akisawa et al., 1999) , and its overexpression may be both necessary and sufficient for metastatic progression of some pediatric tumors Yu et al., 2004) . In order to determine whether 4.1B expression is regulated in mammary epithelia in a similar manner to ERM proteins, we examined the expression pattern of the ERM proteins during postpubertal mammary gland development. Using an antibody that recognizes ezrin and crossreacts with radixin and moesin, these proteins were found to be present at high levels at the apical membranes in the virgin mammary gland (Figure 2a , arrow). We further found that ERM expression decreases dramatically during the proliferative stage of pregnancy and the differentiated stage of lactation before returning to high levels during late involution (Figure 2b- (Tran et al., 1999; Parra et al., 2000; Charboneau et al., 2002) , we found that 4.1B also localizes to the membrane and cytoplasm in individual MDA-MB 436 cells, which do not form normal cell-cell contacts ( Figure 3b ), and is concentrated at the tips of cell processes at apparent points of adhesion to the culture dish. Interestingly, 4.1B expression could be detected around and in the nuclei of these cells even though no such nuclear localization was apparent in mammary tissue sections. Similar results were seen with other mammary cell lines (data not shown). 4.1B contains a putative nuclear localization signal (NLS) (KRRK), as well as an upstream casein kinase II site (SAAE), a common feature in proteins containing an NLS (Kittiniyom et al., 2004) . Furthermore, 4.1B has been shown to translocate from the plasma membrane into the nucleus in PC12 cells following differentiation (Gascard et al., 2004) , and the 4.1 family members merlin, ezrin, and 4.1R localize within the nucleus under some conditions (Mattagajasingh et al., 1999; Batchelor et al., 2004; Muranen et al., 2005) . To exclude the possibility that the observed nuclear localization of 4.1B was due to nonspecific staining by the 4.1B antibody, we created a GFP-4.1B fusion construct (pEFGP-4.1B) in order to monitor the localization of the exogenous protein without having to rely on the antibody. MCF-10A cells, which also exhibit nuclear staining for this protein, were transfected with pEGFP-4.1B or pEGFP alone and fixed 24 h post-transfection. GFP (Figure 3d and g) and 4.1B (Figure 3e and h) localization were determined by immunofluorescence, and nuclei were stained with Hoechst 33342 (Figure 3f and i). Our results indicate that although transfection with pEGFP alone results in GFP localization throughout the cell, GFP tagged with 4.1B is excluded from the nucleus. Similar results were seen in other mammary cell lines (data not shown). Consistent with these findings, Western blots of nuclear and cytoplasmic fractions of MDA-MB 436 and MCF-10A cell lines indicated that the nuclear fractions contained a distinct set of bands, including a prominent band of over 210 kDa, that were not present in the cytoplasmic fractions. Reprobing these blots with a 4.1B antibody that had been preincubated with the full-length protein confirmed that these distinct nuclear bands were in fact nonspecific (data not shown). We conclude, therefore, that although 4.1B contains a putative NLS, it does not localize to the nucleus in mammary cell lines under any of the conditions used in the experiments described here.
4.1B inhibits mammary epithelial cell proliferation but does not influence cell survival
Previous reports have indicated that cells transfected with a cDNA encoding the partial 4.1B construct, DAL-1, demonstrate growth suppression as measured by cell counts and growth curve analysis (Tran et al., 1999; Gutmann et al., 2001; Charboneau et al., 2002; Robb et al., 2005) . One report showed a slight induction in apoptosis in cells overexpressing DAL-1 (Charboneau et al., 2002) . Given our findings that 4.1B is expressed by mammary epithelia during pregnancy, a period of active cell proliferation, but not during involution, a period of extensive apoptosis, we sought to better understand the mechanism by which 4.1B regulates cell growth and survival.
To determine whether 4.1B expression results in increased apoptosis, we first induced overexpression of DAL-1 in the inducible cell line MCF7-DAL1 (Charboneau et al., 2002) by the addition of muristerone for 96 h. Lysates were collected and immunoblotted for 4.1B to insure overexpression of the protein, and for cleaved-PARP, whose expression increases during the induction of apoptosis (Figure 4a ). Our results indicate no increase in cleaved-PARP protein levels. We also assessed the total percentage of cells undergoing apoptosis 48 and 96 h postinduction by the TUNEL assay to measure DNA fragmentation. Pycnotic TUNEL-positive nuclei, as shown in Figure 4b , were counted (Figure 4c) . Although there was a slight increase in the percentage of apoptotic cells 96 h after the induction of apoptosis, the increase was small (o1% of total cells counted;
We next determined the effect of overexpression of 4.1B on proliferation as measured by BrdU incorporation and Ki67 expression. MCF7-DAL1 cells induced to overexpress DAL-1 for 48 or 96 h were pulsed with BrdU for 2 h, fixed, immunolabeled for BrdU, and counterstained with Hoechst 33342. We found a decrease in the percentage of BrdU-positive cells 96 h postinduction (P ¼ 0.048) (Figure 5a ). MCF7-DAL1 cells were also immunolabeled for Ki67 expression, another marker of cell proliferation (Gerdes et al., 1984) , 48 and 96 h postinduction. We found a significant decrease in the percentage of Ki67-positive cells both at 48 (P ¼ 0.03) and 96 (P ¼ 0.008) h postinduction ( Figure 5b ). Taken together, these results quantitatively indicate that the overexpression of DAL-1 in MCF7-DAL1 cells causes a significant reduction in cellular proliferation.
To determine whether intact protein 4.1B also inhibits proliferation, we repeated the BrdU and Ki67 assays with full-length 4.1B in MCF-10A and SKBR3 cells. Cells were transiently transfected with pEGFP or pEGFP-4.1B and pulsed for 2 h with BrdU 48 or 96 h post-transfection. For these assays, we immunolabeled for BrdU and then examined the number of BrdUlabeled GFP-positive cells. Compared to cells expressing only pEGFP, cells expressing elevated levels of 4.1B demonstrated a significant decrease in the percentage of BrdU-positive cells at both 48 and 96 h postinduction in both the MCF-10A (48 h: P ¼ 0.004; 96 h: P ¼ 0.004) and the SKBR3 (48 h: P ¼ 0.009; 96 h: P ¼ 0.004) mammary lines (Figure 5c and e). The percentage of Ki67-labeled GFP-positive cells at both 48 and 96 h post-transfection was also significantly reduced in both the MCF-10A (48 h: P ¼ 0.005; 96 h: P ¼ 0.047) and the SKBR3 (48 h: P ¼ 0.02; 96 h: P ¼ 0.004) cell lines ( Figure  5d and f). Our results indicate that 4.1B mediates growth suppression primarily through the inhibition of proliferation. Although we did observe a slight increase in apoptosis in cells that had been induced to overexpress DAL-1, the percentage of cells undergoing apoptosis The decreased incorporation of BrdU in 4.1B-overexpressing cells suggests that these cells are becoming arrested at some point in the cell cycle, as they are not progressing through S phase. Furthermore, because Ki67 is expressed throughout all stages of the cell cycle except early G 1 and G 0 (Gerdes et al., 1984) , the significant reduction in Ki67 expression observed in 4.1B-overexpressing mammary cells suggests that this protein induces a G 0 /G 1 cell cycle arrest. Cell cycle progression through the G 1 /S transition requires pRb to be hyperphosphorylated, allowing it to dissociate from and permit the activation of the transcription factor E2F (Chau and Wang, 2003) . Cells arrested in G 0 /G 1 thus exhibit a decrease in pRb hyperphosphorylation. We assessed the pRb levels in MCF7-DAL1 cells after 72 h of induction with muristerone by Western blot analysis, and found a decrease in the level of hyperphosphorylated pRb (Figure 6a ), supporting the idea that 4.1B overexpression results in a G 0 /G 1 arrest. In addition, we examined the levels of cyclin A and cyclin D. Cyclin A expression is induced by E2F-mediated transcription during late G 1 and forms a complex with cdk2, which is necessary for progression into and through S phase. Cyclin A is upregulated in S and G 2 phase and downregulated in G 1 . Cyclin D expression is induced during early G 1 as cells exit G 0 , when it forms a complex with cdk4/6 and phosphorylates pRb, and is thus critical for cell cycle activation (Stull et al., 2004) . Levels of cyclin D remain high throughout the remainder of the cell cycle. We found no change in cyclin D levels in cells overexpressing DAL-1, but observed a marked inhibition of cyclin A expression. Collectively, our findings indicate that 4.1B functions by causing cells to arrest in G 1 .
Protein 4.1B does not mediate its growth inhibitory effect through the MAPK, Akt, or JNK signaling pathways
We have demonstrated that 4.1B mediates its growth suppressive function by inducing a G 1 cell cycle arrest. Two signal transduction pathways that are commonly implicated in mediating cell cycle progression through G 1 are the MAPK and PI3K/Akt pathways. The 4.1 family members ezrin and merlin have been shown to regulate these signaling cascades (Gautreau et al., 1999; Fraenzer et al., 2003) . In addition, DAL-1 can induce JNK phosphorylation in IOMM-Lee meningioma cells (Robb et al., 2005) . To determine whether 4.1B mediates its growth inhibitory effect by altering MAPK, Akt, or JNK signaling, we analysed lysates from MCF7-DAL1 cells that had been induced to overexpress DAL-1 by Western blot analysis using phospho-specific antibodies against p44/42 MAPK, Akt, and JNK. We found no changes in the levels of either total or phosphorylated forms of p44/42 or Akt (Figure 6b ) or JNK (Figure 6c ), indicating that changes in MAPK, Akt, and JNK activity are not required in mammary carcinoma cells to induce G 1 arrest.
4.1B inhibits erbB2 phosphorylation
ErbB2 (also called HER2) is a member of the erbB family of receptor tyrosine kinases that includes the epidermal growth factor receptor (EGFR, also called erbB1 and HER1), erbB3 (HER3), and erbB4 (HER4). These receptors are activated by EGF-and neuregulinrelated proteins. Upon ligand binding, EGFR, erbB3, and erbB4 form heterodimers, with erbB2 being the preferred heterodimerization partner (Tzahar et al., 1996) . The expression and activation of erbB2 and EGFR are necessary for normal mammary ductal growth and increase in mammary epithelia during puberty and pregnancy, times when mammary epithelial cells are undergoing high rates of proliferation (Sebastian et al., 1998; Stern, 2003) . Furthermore, erbB2 is a major target of breast cancer treatments, as overexpression of this protein occurs in 20-40% of breast tumors and is associated with poor prognosis (Allred and Mohsin, 2000) . ErbB2 may indirectly interact with 4.1B through the CD44 transmembrane glycoprotein, which interacts Figure 6 Effect of 4.1B overexpression on cell cycle and cell signaling molecules. MCF7-DAL1 cells were induced to overexpress DAL-1 for 72 h (a, b) or for 24, 48, and 72 h (c). Equal concentrations of cell lysates were subjected to Western blot analysis, and blots were probed for (a) the cell cycle proteins pRb, cyclin A, and cyclin D, (b) the signal transduction molecules phospho-Akt, total Akt, phospho-p44/42 MAPK, and total p44/42 MAPK, or (c) phospho-JNK and total JNK. All blots were stained with Ponceau S and probed for a loading control, and tubulin or actin was included as a representative loading control from one of the blots in each panel. Note that pRb hyperphosphorylation and cyclin A levels were decreased in cells induced to overexpress DAL-1 (a), while no change was seen in cyclin D (a), phospho-Akt, Akt, phospho-p44/42, p44/42 (b), phospho-JNK or total JNK levels (c) in DAL-1-overexpressing cells 4.1B regulates mammary epithelial proliferation R Kuns et al with erbB2 and EGFR in mammary carcinoma cells (Wobus et al., 2002; Ghatak et al., 2005) and with 4.1 proteins through its C-terminal domain (Ponta et al., 2003) . As loss of erbB2 expression or activity can inhibit proliferation of mammary carcinoma cells (JhabvalaRomero et al., 2003; Faltus et al., 2004; Chu et al., 2005) , including the MCF-7 cell line, we tested the possibility that 4.1B regulates mammary epithelial cell proliferation at least in part by regulating erbB2 activity. Compared to controls, MCF-7 cells induced to express DAL-1 demonstrated a nearly total reduction in erbB2 phosphorylation without any decrease in the total levels of erbB2 (Figure 7a ). We therefore tested whether 4.1B disrupted the formation of erbB2-EGFR or erbB2-erbB3 heterodimers. In both the absence and presence of induced levels of 4.1B, EGFR remained associated with erbB2 ( Figure 7b) . In contrast to EGFR, erbB3 did not constitutively associate with erbB2 in these cells. However, following the addition of neuregulin, we did observe erbB2-erbB3 heterodimers, but they also were not dissociated in the presence of 4.1B (data not shown). We were unable to detect significant quantities of erbB4 in these cells. These data suggest that although 4.1B can inhibit erbB2 phosphorylation, it does so without disrupting the formation of erbB receptor heterodimers.
We next tested the possibility that 4.1B disrupted interactions between erbB2 and CD44. However, in coimmunoprecipitation assays, the induction of 4.1B had no effect on CD44-erbB2 interactions in MCF-7 cells (Figure 7c ). Thus, reduced erbB2 phosphorylation resulting from 4.1B induction may contribute to 4.1B-mediated cell cycle arrest without disrupting erbB receptor heterodimers or other erbB2 interactions with transmembrane proteins that promote erbB2 activation and signaling.
Loss of protein 4.1B results in increased mammary epithelial cell proliferation during pregnancy
To determine if loss of protein 4.1B leads to proliferative abnormalities in vivo, we examined mammary glands from different postpubertal developmental stages in 4.1B knockout mice. These mice have an apparently normal phenotype and do not develop tumors of the mammary gland (Kissil et al., manuscript in preparation). Indeed, we found no significant morphological differences between the virgin mammary glands of wildtype and 4.1B-null animals (compare Figure 8a and d) . However, we did observe dramatic differences in pregnant glands compared to stage-matched wild-type controls (compare Figure 8b and e) . The appearance of the tissues indicated an overall increase in the numbers of alveoli and ducts during pregnancy. This phenotype did not persist into lactation (compare Figure 8c and f) . In order to determine whether this altered morphology was due to an increase in epithelial cell proliferation, we assessed Ki67 expression in the epithelium of these glands as Ki67 is a frequently used marker of proliferation in tissues (Scholzen and Gerdes, 2000) . Although we found no effect on cell proliferation as measured by Ki67 expression in the mature virgin or lactating mammary gland (data not shown), we did observe a significant increase (from 49.671.3 to 80.274.8%; P ¼ 0.0009) in the percentage of proliferating epithelial cells in the pregnant wild-type gland in comparison to region-matched 4.1B knockout glands (Figure 9a-c) . At no point in any stage of mammary development did we observe altered levels of apoptosis, as assessed by TUNEL labeling (data not shown). Together, our results suggest that the upregulation of 4.1B during pregnancy regulates the proliferative levels of luminal epithelial cells by regulating the progression of these cells through G 1 .
Discussion
We demonstrate here that 4.1B is not expressed in the normal mouse virgin mammary gland epithelium and Figure 7 Effects of 4.1B on erbB2 phosphorylation. (a) MCF7-DAL1 cells were induced to overexpress DAL-1 by the addition of Muristerone A for 48 h. Equal concentrations of cell lysates from induced ( þ ) and uninduced (À) cells were subjected to Western blot analysis, and the resulting blots were probed for phosphoerbB2, total erbB2, DAL-1, or tubulin as a loading control. Note that in the presence of DAL-1, erbB2 phosphorylation is dramatically reduced while total erbB2 levels are unchanged. (b) MCF7-DAL1 cells were induced as above and then equal concentrations of lysates were immunoprecipitated for erbB2 and EGFR and subjected to Western blot analysis. The resulting blots were probed for erbB2 and EGFR. Note that ErbB2 and EGFR co-immunoprecipitate both in the absence (À) and presence ( þ ) of DAL-1. (c) MCF7-DAL1 cells were induced to overexpress DAL-1, and then equal concentrations of lysates were immunoprecipitated for erbB2 and CD44. Lysates and immunoprecipitates were then assessed for erbB2 and CD44 expression by Western blot analysis. Note that erbB2 and CD44 co-immunoprecipitate both in the absence (À) and presence ( þ ) of DAL-1 4.1B regulates mammary epithelial proliferation R Kuns et al that loss of 4.1B does not influence cell proliferation in virgin 4.1B-null mice. In contrast, 4.1B expression is dramatically induced in mammary epithelium during pregnancy, and pregnant 4.1B-null mice demonstrate increased mammary epithelial proliferation. As cells pass this highly proliferative state and move into the fully differentiated state of lactation, 4.1B expression is no longer evident, and remains undetectable during the apoptotic involuting stage. Furthermore, loss of 4.1B does not affect proliferation of epithelial cells in the lactating or involuting mammary glands. In support of these data, we find that 4.1B is expressed at very low levels in both immortalized mammary epithelial and carcinoma cell lines and that overexpression of 4.1B in these cells causes them to arrest in G 1 . These results demonstrate a unique role for 4.1B in the regulation of epithelial cell proliferation in the mammary gland. Our findings suggest that 4.1B may not function to suppress cell growth in a manner that is analogous to merlin or other tumor suppressor proteins. Since it is not expressed in virgin mouse mammary epithelial cells, 4.1B does not appear to function by maintaining or inducing epithelial cell quiescence. Furthermore, the lack of mammary tumors in 4.1B-null mice indicates that loss of 4.1B is not likely to be sufficient to promote tumorigenesis. In contrast, loss or mutational inactivation of merlin is sufficient to induce tumor formation (Rouleau et al., 1993; Trofatter et al., 1993; McClatchey et al., 1998) . It is nonetheless possible that 4.1B cooperates with other tumor suppressor genes, including other members of the 4.1 family, to promote tumor formation. In addition, because multiparity has been associated with increased breast cancer risk (Whiteman et al., 2004; Hall et al., 2005) , it is possible that loss of 4.1B may promote mammary gland tumors after multiple pregnancies, although this has not yet been observed in 4.1B-null mice (Kissil et al., manuscript in preparation) .
It has been previously reported that ectopic expression of DAL-1, which contains the growth suppressive function of full-length 4.1B, results in the induction of apoptosis, with 5-8% of DAL-1-overexpressing cells becoming apoptotic as assessed by TUNEL or Annexin V labeling (Charboneau et al., 2002; Robb et al., 2005) . It was concluded from these findings that DAL-1 may reduce growth, in part, by altering cell survival. Here, we measured apoptotic induction by assaying cleaved-PARP expression levels as well as DNA fragmentation by TUNEL labeling and did not observe the same significant increase in apoptosis. Although 4.1B may indeed induce apoptosis, our data suggest that this is not the case under all conditions. Figure 8 Morphology of virgin, pregnant, and lactating mammary glands in the wild-type and 4.1B knockout mice. The fourth pair of mammary glands from (a, d) 8 weeks virgin, (b, e) 13.5 dpc pregnant, and (c, f) 9 dpp lactating wild-type (a-c) and 4.1B-null (d-f) mice were paraffin-embedded and sectioned. Nuclei were stained with hematoxylin. Images were taken with a 5 Â objective to show the overall morphology of the glands. Note the apparent increase in the density of ductal and alveolar epithelial cells in the 4.1B-null versus wild-type glands
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We have shown, however, through BrdU and Ki67 labeling studies that exogenous 4.1B significantly inhibits cellular proliferation at a specific stage of the cell cycle. The BrdU results, which indicate that 4.1B-overexpressing cells are significantly inhibited in their ability to progress through S-phase, are supported by the observation that cyclin A levels are decreased in 4.1B-overexpressing cells. The Ki67 results, obtained both in vitro and in vivo, indicate that 4.1B-overexpressing cells are either entering G 0 or arresting in the G 1 phase of the cell cycle and are supported by the decrease observed in pRb hypophosphorylation. The change in pRb phosphorylation levels indicates that cells are not progressing through the G1/S-phase transition. Furthermore, cyclin D levels did not change upon 4.1B overexpression, indicating that cells are not exiting the cell cycle and entering G 0 . Taken together, these results indicate that 4.1B mediates a cell cycle arrest in G 1 in mammary cell lines. Although G 1 cell cycle arrest can be mediated in some systems through the JNK, MAPK, and/or Akt pathways, we did not observe changes in phospho-JNK, phospho-Akt, or phospho-p44/42 levels upon 4.1B overexpression, suggesting that other signaling mechanisms are affected by 4.1B to regulate growth suppression. In contrast, recent studies from one of our laboratories have suggested that 4.1B functions to regulate cell growth in meningioma cells by modulating JNK signaling (Robb et al., 2005) . 4.1B may therefore mediate its growth inhibitory effect differently in mammary cells compared to meningioma cells.
It has also recently been shown that 4.1B interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate its substrates (Singh et al., 2004) . 4.1B may mediate its growth inhibitory effect by interacting with PRMT3 and thus modulating its ability to methylate its substrates. Another possibility is that the interaction between 4.1B and the tumor suppressor in lung cancer-1 (TSLC1) is required for 4.1B-mediated growth suppression (Yageta et al., 2002) . In addition to being lost in NSCLCs, TSLC1 has recently been shown to be lost in meningiomas; both of these tumor types also exhibit frequent 4.1B loss (Surace et al., 2004) . Interestingly, we have found that, similar to 4.1B, TSLC1 is expressed at low levels in virgin and involuting mouse mammary glands, but is upregulated during pregnancy as well as during lactation (data not shown).
Our finding that DAL-1 can inhibit the constitutive phosphorylation of erbB2 in MCF-7 cells suggests that 4.1B may regulate mammary epithelial cell proliferation in part by regulating erbB2 activation. However, erbB2 signals through the MAPK and Akt pathways to influence cell proliferation (Yarden and Sliwkowski, Figure 9 Ki67 expression in wild-type and 4.1B knockout pregnant mammary glands. The fourth pair of mammary glands from E13.5 pregnant wild-type and 4.1B knockout mice were dissected, and the approximately 3 mm region closest to the nipple was removed, paraffin-embedded, and sectioned. The sections were immunolabeled for Ki67 (black) and counterstained with hematoxylin (gray). Shown are epithelial regions from (a) wild-type and (b) 4.1B knockout glands. (c) At least 500 epithelial nuclei were counted in random fields, and the counts from both the right and left glands were then averaged to determine the percentage of Ki67-postive nuclei for each mouse. Four wild-type and 4.1B knockout mice were used to obtain the results, which are shown 7s.e.m. ***Po0.001. Note the significant upregulation in Ki67 expression in the mammary epithelium of the pregnant 4.1B-null versus wildtype mice 4.1B regulates mammary epithelial proliferation R Kuns et al 2001) and our data indicate that 4.1B induces a G 1 arrest independent of altered MAPK or Akt activity. It is therefore possible that other signaling cascades that influence pRb are also regulated by erbB2. Alternatively, the loss of erbB2 phosphorylation may be an indirect effect of 4.1B induction that could amplify a number of signals that result in cell cycle arrest. Nonetheless, our studies raise the intriguing possibility that 4.1B can influence erbB receptor activation during pregnancy and in mammary carcinoma cells with elevated levels of EGFR or erbB2 through a mechanism that does not influence receptor heterodimerization. Although it is unclear how 4.1B influences erbB2 phosphorylation, one possible way could be through the recruitment of a protein tyrosine phosphatase that, like 4.1B, possesses a FERM domain and could bind the C-terminus of 4.1B (e.g. Cuppen et al., 1999) . Although 4.1B has previously been reported to localize to the nucleus, it has only been shown to do so in nonproliferating, differentiated cells (Gascard et al., 2004) , in contrast to the highly proliferative mammary cell lines used here and the undifferentiated mammary epithelia in the nonpregnant mammary gland. It is therefore possible that, like other 4.1 family members, 4.1B does localize to the nucleus but only under distinct cellular conditions. Although we never observed nuclear 4.1B at any stage of mammary development, it is possible that 4.1B translocates to the nucleus of other cell types after the transition from proliferative to differentiated states.
In summary, our results suggest that 4.1B may only be functional when mammary epithelial cells become highly proliferative during pregnancy. We therefore propose that 4.1B is upregulated during pregnancy, and possibly similar states of increased proliferation in other cell types, as a means of modulating external proliferative signals. Furthermore, we hypothesize that although loss of the 4.1B gene in mammary epithelia does not itself result in tumor formation, it may exacerbate the rate of tumor cell proliferation by relieving cells of an antiproliferative signal that would otherwise prevent continued cell growth. Further studies utilizing the 4.1B-null mice will be required to better understand the role of 4.1B in mammary carcinogenesis.
Materials and methods
Mice
Female 8-week-old wild-type C57BL/6 and C57BL/6-129Sv/J mice were purchased from Jackson Laboratories. Generation of the 4.1B-null mice is described elsewhere (Kissil, 2005) . Dams were euthanized using a lethal dose of isoflurane and tissues were harvested as described below from 8-week-old virgin, 13.5 dpc pregnant, 9 dpp lactating, and 5 dpw involuting animals.
Immunohistochemistry
For quantitative analyses, an approximately 3 mm region nearest the nipple of the right and left fourth mammary glands was dissected from animals at each stage of mammary gland maturation. In some cases, whole mammary tissues were also dissected. Tissues were fixed overnight in 4% paraformaldehyde at 41C and washed three times for 20 min per wash in PBS before being embedded in paraffin. Sections (5 mm) were deparaffinized with xylene followed by rehydration with a graded ethanol series. Antigen retrieval was performed with DAKO target retrieval solution (S1700, DAKO Corporation) as per the manufacturer's instructions. The sections were blocked in 3% hydrogen peroxide/PBS for 15 min and in 10% normal goat serum (NGS) in PBS for 60 min, and then incubated overnight with the following primary antibodies at 41C: a rabbit anti-4.1B polyclonal antibody (Ezequiel Surace and David Gutmann, unpublished results, 2005 ; 1 : 500), a rabbit anti-ezrin (C-19) polyclonal antibody (Santa Cruz; 1 : 100), rabbit anti-E-cadherin (H-108) polyclonal antibody (Santa Cruz; 1 : 250), or a mouse anti-Ki67 monoclonal antibody (NCL-L-Ki67-MMI, Novocastra; 1 : 50) in 10% NGS at 41C. After being washed, the sections were incubated with biotinylated secondary antibodies (BA-1000, BA-9500, BA-9500; Vector Laboratories; 1 : 200) for 25 min. The sections were then incubated with the Vectastain Elite ABC reagent (PK-6100; Vector Laboratories), developed with the Vector NovaRed Substrate Kit (SK-4800; Vector Laboratories), and counterstained with hematoxylin (H-3401, Vector Laboratories) or processed for immunofluorescence with Alexa-Fluorconjugated secondary antibodies (A-11029, A-11030, A-11034, A-11035, Molecular Probes; 1 : 500) and Hoechst 33342 (Molecular Probes; 1 : 2000) . Images were obtained with a Zeiss Axioskop 40 microscope using a Â 63 oil-immersion objective (Carl Zeiss Inc.).
Cell culture
All cell lines were obtained from and grown according to the specifications of ATCC except the MCF7-DAL1 cell line, which was grown as previously described (Charboneau et al., 2002) . DAL-1 expression was induced in the MCF7-DAL1 cell line by the addition of 2 mM Muristerone A (Invitrogen) or 5 mM Ponasterone A (Invitrogen) for the indicated length of time. In some experiments, cells were pulsed with 10 ng/ml neuregulin-1b (R&D Systems) for 10 min.
Western blot analysis and immunoprecipitations
Cultured cells were washed in PBS and lysed (20 mM Tris-HCl pH 7.4, 25 mM NaCl, 3 mM MgCl 2 , and 0.5% NP-40 plus protease inhibitors); mammary tissues were lysed by sonication in the same lysate buffer. Lysates were cleared by centrifugation (14 000 r.p.m. at 41C) for 10 min, and the protein concentration of the resulting supernatant was obtained by the Bradford assay before Laemmli buffer was added. The samples were boiled for 5 min before being loaded in equal concentrations onto a 5.5, 7.5, or 12% SDS-polyacrylamide gel. The protein was transferred onto nitrocellulose membrane and probed overnight with the indicated antibodies at 41C. Two different rabbit anti-4.1B polyclonal antibodies were used as previously described (Tran et al., 1999) at 1 : 2000. Additional antibodies used were mouse anti-cleaved-PARP monoclonal antibody (19F4, Cell Signaling Technology; 1 : 2000) , mouse anti-alpha-tubulin monoclonal antibody (DM1A, NeoMarkers; 1 : 1000), rabbit anti-E-cadherin (H-108) polyclonal antibody (Santa Cruz; 1 : 1000), goat anti-actin (I-19) polyclonal antibody (Santa Cruz; 1 : 1000), rabbit antipRb (C-15) polyclonal antibody (Santa Cruz; 1 : 100), mouse anti-cyclin D1 (DCS6) monoclonal antibody (2926, Cell Signaling; 1 : 2000), rabbit anti-phospho-p44/42 MAP kinase polyclonal antibody (9101, Cell Signaling; 1 : 1000), mouse anti-EGFR monoclonal antibody (Upstate; 1 : 500), mouse anti-erbB2 monoclonal antibody (Calbiochem; 1 : 500), rabbit anti-phospho-erbB2 polyclonal antibody (Upstate; 1 : 2000), and mouse anti-human CD44 monoclonal antibody (Hermes-3; ATCC; 1 : 50). The following antibodies were generously provided: rabbit anti-cyclin A (C-19) polyclonal antibody (Santa Cruz; 1 : 1000) from Erik Knudsen (University of Cincinnati); rabbit anti-phospho-JNK polyclonal antibody (Cell Signaling; 1 : 1000) and rabbit anti-JNK polyclonal antibody (Cell Signaling; 1 : 500) from Mihail Iordanov (Oregon Health & Science University); rabbit anti-phosphoAkt polyclonal antibody (9271, Cell Signaling; 1 : 1000), rabbit anti-Akt rabbit polyclonal antibody (9272, Cell Signaling; 1 : 1000), and rabbit anti-p44/42 MAP kinase polyclonal antibody (9102, Cell Signaling; 1 : 1000), all from Eliot Spindel (Oregon National Primate Research Center). Blots were washed and probed with HRP-conjugated secondary antibodies (170-6515, 170-6516; BioRad; 1 : 1000), (sc-2020, Santa Cruz; 1 : 1000) for 90 min, washed, and developed with chemiluminescent substrates for 5 min (34080, 34095; Pierce).
For immunoprecipitations, equal concentrations of lysates were precleared for 30 min at 41C with Protein G Plus/Protein A Agarose (IP10, Oncogene) or protein A Sepharose beads (170-0780-01, Amersham). Lysates were then cleared and incubated with the following antibodies overnight at 41C: mouse anti-EGFR monoclonal antibody (05-101, Upstate; 1 : 50), mouse anti-erbB2 monoclonal antibody (c-neu Ab-3, OP15, Calbiochem; 1 : 50), rabbit anti-erbB3 (C-17) polyclonal antibody (sc-285, Santa Cruz; 1 : 200), and mouse anti-CD44 monoclonal antibodies, which were generated from the Hermes-3 hybridoma (HB-9480, ATCC; 1 : 10). The protein A/G agarose or protein A Sepharose beads, as described above, were washed and incubated with the lysates for 90 min at 41C. The beads were then collected and washed five times in lysis buffer. Laemmli buffer was added to the lysates, boiled for 5 min, and loaded in equal concentrations onto a 5 or 7.5% SDS-polyacrylamide gel.
Construction of pEGFP-4.1B
The stop codon of 4.1B within the pcDNA3-4.1B vector was mutated and a BamHI site created by mutagenesis using the following primers: forward (5 0 -CCA GAA GAT GGA GAG GAT GGA TCC GAG GAA TAA CTT AGC TTG CAC-3 0 ) and reverse (5 0 -GTG CAA GCT AAG TTA TTC CTC GGA TCC ATC CTC TCC ATC TTC TGG-3 0 ). In addition, a BamHI site was created upstream of the 4.1B start site by an additional mutagenesis step using the following primers: forward (5 0 -GGC GCG CCC GGG ATC CCT GCT GAT C-3 0 ) and reverse (5 0 -GAT CAG CAG GGA TCC CGG GCG CGC C-3 0 ). The resulting pcDNA3-4.1B vector contained 4.1B flanked by BamHI sites and a mutated stop codon. The mutated pcDNA3-4.1B and the pEGFP-N3 (BD Biosciences) vectors were both digested with BamHI. The resulting DNA fragments were separated on an agarose gel, and the resulting 4.1B fragment as well as the linearized pEGFP vector was purified and then ligated. The resulting pEGFP-4.1B clones were verified to express the 4.1B-GFP fusion protein by transfection into MCF-10A cells, followed by immunolabeling for 4.1B and GFP.
BrdU incorporation assays and immunofluorescence
Cells were plated on coverslips and transfected with pEGFP or pEGFP-4.1B (described below) using Lipofectatime 2000 (Invitrogen) or induced to express DAL-1 with Muristerone A as described above. The cells were incubated for the indicated times, and the media were changed every 24-48 h. For the BrdU incorporation assays, BrdU (10 mM; Sigma) was added to cell media for 2 h prior to fixation. All cells were then washed in PBS and fixed in 4% paraformaldehyde for 15 min. After washing again in PBS, the cells for the BrdU assay were denatured with 2 N HCl for 20 min, and then washed extensively in PBS (4 Â 20 min). For all immunofluorescence procedures, cells were blocked in 10% normal goat serum in PBS with 0.005% Triton X-100, and then probed with the indicated antibodies overnight. Antibodies used were rabbit anti-4.1B polyclonal antibody (Tran et al., 1999) , mouse antiBrdU (Ab-2) monoclonal antibody (Oncogene Research Products; 1 : 50), mouse anti-Ki67 monoclonal antibody (NCL-L-Ki67-MMI, Novocastra; 1 : 50), rabbit anti-GFP polyclonal antibody (sc-8334, Santa Cruz; 1 : 200), and Hoechst 33342 (Molecular Probes; 1 : 2000) . The coverslips were then washed and probed with Alexa-Fluor-conjugated secondary antibodies (A-11029, A-11030, A-11034, A-11035, Molecular Probes; 1 : 500) and Hoechst 33342 (Molecular Probes; 1 : 2000) for 90 min before being washed and mounted. For the BrdU and Ki67 assays, MCF7-DAL-1 cells7mur-isterone were assessed for BrdU or Ki67 labeling; GFPpositive MCF-10 and SKBR3 cells transfected with pEGFP or pEGFP-4.1B were assessed for BrdU or Ki67 labeling and compared to untransfected control cells.
TUNEL assay
MCF7-DAL1 cells were plated on coverslips and induced to express DAL-1 with 2 mM Muristerone A (Invitrogen). The cells were incubated for the indicated times, and the media were changed every 24-48 h. The coverslips were washed briefly in PBS and fixed in 4% paraformaldehyde for 1 h at room temperature. They were washed again in PBS and then permeabilized in 0.1% Triton X-100 in 0.1% sodium citrate and PBS for 2 min on ice. TUNEL labeling was performed using the In situ Cell Death Detection Kit, TMR red (Roche) according to the manufacturer's instructions. Both positive and negative controls were included with each experiment. Nuclei were labeled with Hoechst 33342 (Molecular Probes) briefly before the final washes. TUNEL-positive nuclei were counted and compared to total nuclei. Images were obtained with a Zeiss microscope using the Â 63 oil-immersion objective (Axioskop 40, Carl Zeiss Inc.).
